Omega Diagnostics (CNSL) Price & Analysis

Compare

4 Followers

CNSL Stock Chart & Stats

2.30 p

-0.05 p(-1.67%)

At close: Jan 09 4:00 PM EST

2.30 p

-0.05 p(-1.67%)

Day’s Range― - ―

52-Week Range1.80 p - 4.33 p

Previous CloseN/A

Volume6.91K

Average Volume (3M)353.57K

Market Cap

£4.52M

Enterprise Value1.16M

Total Cash (Recent Filing)£3.59M

Total Debt (Recent Filing)£237.00K

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Jul 29, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding237,950,650

10 Day Avg. Volume111,535

30 Day Avg. Volume353,573

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.64

Price to Sales (P/S)0.87

P/FCF Ratio-51.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)£7.50M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low leverage (debt/equity 0.03) and mid-teens ROE provide durable financial flexibility. Low debt reduces refinancing and interest burden risk, supporting capital allocation for R&D or capacity and helping the company withstand sector cyclicality over the next several quarters.

High Gross And Net MarginsA 60% gross margin and near-19% net margin indicate strong product-level economics and pricing power in core diagnostics. These margins create a buffer vs cost inflation and support reinvestment or margin recovery if operational efficiencies improve, underpinning medium-term profitability.

Diversified IVD Business ModelOwning manufacturing plus mixed own-brand and B2B distribution gives structural revenue diversification and control over quality and margins. Stable demand from healthcare, labs and clinical markets supports predictable product volumes and resilience across healthcare cycles.

Bears Say

Declining Revenue TrendSustained negative top-line growth (double-digit and mid-single-digit declines) signals loss of sales momentum or market share. Without reversing revenue trends, fixed costs and R&D leverage may pressure margins and make long-term margin recovery or investment scale harder.

Weak Cash GenerationVery weak cash conversion and a steep negative free cash flow trend indicate liquidity strain and poor working capital management. This limits ability to fund growth, capital expenditure or absorb shocks without tapping reserves or external financing over the medium term.

Operational InefficienciesNegative EBIT margin while gross margin is strong points to high operating costs or SG&A pressure. Persistent inefficiencies reduce retained earnings and could impede sustainable profitability unless structural cost reductions or productivity gains are implemented.

Omega Diagnostics News

Cambridge Nutritional Sciences Leadership Increases Shareholdings

Omega Diagnostics ( ($GB:CNSL) ) has provided an update. Cambridge Nutritional Sciences plc announced that Carolyn Rand, Non-Executive...

4M ago

Cambridge Nutritional Sciences Reports Revenue Decline but Improves Gross Margin

Omega Diagnostics ( ($GB:CNSL) ) has shared an update. Cambridge Nutritional Sciences reported a decrease in revenue for...

4M ago

Cambridge Nutritional Sciences to Announce Half Year Results and Host Investor Presentation

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences plc has announced it will release...

4M ago

Cambridge Nutritional Sciences Announces AGM and Annual Report Release

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences plc has announced the finalization of...

7M ago

Cambridge Nutritional Sciences Grants Share Options to CFO

Omega Diagnostics ( ($GB:CNSL) ) has provided an update. Cambridge Nutritional Sciences Plc has announced the granting of...

7M ago

Cambridge Nutritional Sciences PLC Reports Strong Financial Performance Amidst Strategic Restructuring

Omega Diagnostics ( ($GB:CNSL) ) has shared an update. Cambridge Nutritional Sciences PLC reported its final results for...

7M ago

Cambridge Nutritional Sciences to Announce Final Results and Host Investor Presentation

The latest update is out from Omega Diagnostics ( ($GB:CNSL) ). Cambridge Nutritional Sciences plc announced it will...

8M ago

Cambridge Nutritional Sciences Appoints New CFO to Bolster Growth

Omega Diagnostics ( ($GB:CNSL) ) has issued an update. Cambridge Nutritional Sciences Plc has appointed Ajay Patel as...

8M ago

Cambridge Nutritional Sciences Appoints New CFO to Drive Growth

Omega Diagnostics ( ($GB:CNSL) ) just unveiled an announcement. Cambridge Nutritional Sciences Plc has appointed Ajay Patel as...

8M ago

Cambridge Nutritional Sciences PLC Adjusts Voting Rights Structure

Omega Diagnostics ( ($GB:CNSL) ) just unveiled an update. Cambridge Nutritional Sciences PLC has announced a change in...

9M ago

CNSL FAQ

What was Omega Diagnostics Group PLC’s price range in the past 12 months?

Omega Diagnostics Group PLC lowest share price was 1.80 p and its highest was 4.33 p in the past 12 months.

What is Omega Diagnostics Group PLC’s market cap?

Omega Diagnostics Group PLC’s market cap is £4.52M.

When is Omega Diagnostics Group PLC’s upcoming earnings report date?

Omega Diagnostics Group PLC’s upcoming earnings report date is Jul 29, 2026 which is in 133 days.

How were Omega Diagnostics Group PLC’s earnings last quarter?

Omega Diagnostics Group PLC released its earnings results on Nov 10, 2025. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.

Is Omega Diagnostics Group PLC overvalued?

According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Omega Diagnostics Group PLC pay dividends?

Omega Diagnostics Group PLC does not currently pay dividends.

What is Omega Diagnostics Group PLC’s EPS estimate?

Omega Diagnostics Group PLC’s EPS estimate is >-0.01.

How many shares outstanding does Omega Diagnostics Group PLC have?

Omega Diagnostics Group PLC has 237,950,650 shares outstanding.

What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?

Omega Diagnostics Group PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.094%.

Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?

Currently, no hedge funds are holding shares in GB:CNSL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Omega Diagnostics Group PLC

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.